Chinese decoction used to treat neurological disorders, in spinal cord injury (SCI). METHODS: In this doubleblind, placebo-controlled study, patients with traumatic SCI and American Spinal Injury Association (ASIA) impairment grades B -D were randomized to receive DHYZ (n = 30) or placebo (n = 30) for 12 weeks. Both groups also received rehabilitation therapy during the study period. Motor and sensory function and activities of daily living (ADL) were assessed before treatment and at 4-week intervals. RESULTS: Significantly more patients in the DHYZ group showed an improved ASIA impairment grade during the treatment period (32.1%) compared with the placebo group (10.3%), and scores for sensory and motor function and ADL at the end of the treatment period were significantly higher in the DHYZ group than in the placebo group. No serious sideeffects were reported. CONCLUSIONS: DHYZ was found to improve neurological function in patients with SCI and may be an effective adjuvant therapy to enhance functional recovery.
Introduction
Spinal cord injury (SCI), which has an annual incidence of 11.5 -53.4 cases/million population in various countries throughout the world, 1, 2 can result in impairments of motor, sensory and autonomic function. 3 The degree of dysfunction has a direct influence on the patient's health-related quality of life, and regeneration of the injured spinal cord is, therefore, an attractive field of basic medical and clinical research. Repair of the spinal cord is a complex biological and cytological process and its mechanisms are, as yet, unclear.
No specific drugs are currently available for the treatment of SCI. Despite much research, methylprednisolone given within 8 h of injury is still the only pharmacological YL Li, LT Li, M Yu et al. Di Huang Yin Zi in spinal cord injury treatment known to ameliorate the neurological dysfunction that occurs at or below the level of the neurological insult. 4 -11 When the traumatic episode is severe, many SCI patients do not recover lost neurological function. 12 Some patients will pursue alternative treatments, such as acupuncture or natural medicine, in search of neurological recovery. Electrical acupuncture (through adhesive surface electrodes) and auricular acupuncture therapies have been shown to improve neurological and functional recovery in acute traumatic SCI patients. 13 In an open-label preliminary clinical trial, 'Raffinee', a formulation of superoxide dismutase-like antioxidants derived from natural products, was found to have therapeutic effects in a small population of patients with SCI. 14 There is increasing evidence that natural medicines and herbal drugs can aid the repair of damaged neurons. Extracts of human placenta and ginsenosides have been shown to promote peripheral axonal regeneration, 15, 16 and herbal drugs such as Ginkgo biloba, danshen and ginseng components have been reported to have neuroprotective effects in injured spinal cord tissues and ischaemic brain. 17 -19 Di Huang Yin Zi (DHYZ) is a traditional Chinese decoction that has been used in neurological disorders since the Song dynasty (approximately 900 years ago) however, there are no reported studies of its use in SCI. This double-blind, randomized, placebo-controlled clinical study investigated the effects of DHYZ on the recovery of spinal cord function after SCI. 20 and an injury level ranging from T2 to L2. Exclusion criteria included the requirement for mechanical ventilation or the presence of concomitant traumatic brain injury, peripheral nerve injury, loss of consciousness or multiple bony fractures.
Patients and methods

PATIENTS
All patients received any necessary initial emergency treatment and surgical intervention for SCI, including surgical bone fusion and fixation. The study protocol was approved by the Ethics Committee of Shandong University, Jinan, China, in conformity with the Declaration of Helsinki and its subsequent amendment. All patients provided written informed consent.
PREPARATION OF DHYZ AND PLACEBO
Di Huang Yin Zi is a combination of 13 herbal drugs. The quality of the constituent herbs was in accordance with the standards set out in the Pharmacopoeia of the People's Republic of China, 2000 edition. 21 The content of known chemical constituents in a tablet of DHYZ derived from 3 g crude herbal mixture was evaluated using high-performance liquid chromatography with electrochemical detection. The shelf life of DHYZ is 1 year.
The placebo and DHYZ were prepared by Jinan Pharmaceutical (Jinan, Shandong, China) as described by Zhang et al. 22 The water extract of the crude herbal materials was processed as described in the
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Pharmacopoeia of the People's Republic of China, 2000 edition. 21 The resulting powder was formed into tablets, each tablet containing 3 g of the crude herbal mixture. The placebo and herbal tablets were identical in shape, size and colour. To minimize the effect of the distinctive smell of herbal preparations on double blinding, the herbal tablets and placebo were all contained in blister packs made from plastic film and aluminium foil, with six tablets in each blister pack. The packs were distributed to the patients by a physician who was not involved in the study. The study investigators and patients were not aware of the identity of the administered medications.
STUDY PROCEDURE
Patients were allocated at random and in equal numbers to a group treated with DHYZ and a group treated with placebo, using a computer-generated randomization procedure performed by a physician who was not involved in patient evaluation. The DHYZ and placebo treatments were commenced when the patients were transferred from a surgical ward to an ordinary ward within the rehabilitation centre.
Patients received either DHYZ (18 g twice daily) or placebo (18 g twice daily) for 12 weeks. During the study period, patients also received inpatient rehabilitation therapy consisting of 2 h of individual physiotherapy and 2 h of occupational therapy on 6 days each week.
PATIENT EVALUATION
Patients were assessed at baseline and after 4, 8 and 12 weeks' treatment with DHYZ or placebo.
The degree of SCI was assessed using the International Standards for Neurologic and Functional Classification of SCI, as developed by ASIA. 20 Spinal cord function was assessed using sensory and motor examinations. For the sensory examination, each of the 28 dermatomes was tested bilaterally for sharp (pinprick) and light-touch sensation. Sharp sensation was tested using a disposable safety pin and light touch was tested with cotton wool; both were scored on a threepoint scale from 0 to 2 (0, absent sensation; 1, hypaesthesia or hyperaesthesia; 2, normal sensation). The maximum score for each of the two sensory examinations was 112, giving a summed maximum score for both sensory examinations of 224.
For the motor examination, a total of 10 myotomes were assessed bilaterally. Muscle strength was scored using a manual muscle testing score of 0 -5 per muscle group (0, no contraction, 1, contraction but no movement, 2, movement with gravity eliminated, 3, movement against gravity but not against resistance, 4, movement against resistance but less than normal, and 5, normal strength). The overall score ranged from 0 to 100.
Activities of daily living (ADL) were scored using the Barthel index 23 (range 0 -100; the higher the score, the greater the independence in ADL). This involves assessments of the extent of assistance needed for feeding, transferring (from chair to bed and back), grooming, toileting, bathing, walking, climbing stairs, dressing, and bowel and bladder functions.
At each time point, patients underwent a basic physical examination including vital signs, laboratory tests and electrocardiography.
Side-effects and tolerability were assessed by the physician/investigator, who recorded all adverse events (reported, elicited or observed) on a case report form, including the date and time of onset, duration, severity, relationship to the study drug and action taken.
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Results were expressed as the mean ± SD. The difference in the percentage of patients showing an improved ASIA impairment grade during the 12-week study period between the groups was assessed using the χ 2 -test. Baseline patient characteristics and sensory, motor and Barthel index scores at each time point during the 12-week treatment period were assessed using the Student's t-test. A P-value of < 0.05 was considered to be statistically significant. All statistical analyses were performed using SPSS ® software version 15.0 (SPSS Inc., Chicago, IL, USA).
Results
The composition of a tablet of DHYZ derived from 3 g crude herbal mixture determined by high-performance liquid chromatography is given in Table 1 . A total of 60 patients were recruited into the study; 30 patients were treated with 18 g DHYZ twice daily and 30 received the placebo tablet. The patients' characteristics are summarized in Table 2 .
No serious side-effects related to the study treatments were observed. Three patients in the DHYZ group and three patients in the placebo group complained of nausea for several days during the first week of treatment; the nausea was treated by massage and had attenuated by the second week in all affected patients. No patient in either group withdrew from the study as a result of medication side-effects.
A total of three patients were withdrawn from the study due to SCI complications that affected the rehabilitation process: two patients in the DHYZ group left the study (one because of symptoms of depression and one because of aggravated urinary tract infection) and one patient in the placebo group did not complete the study because of deep vein thrombosis of the lower limb.
These three patients were all withdrawn after 4 weeks' treatment. Consequently, data from 28 patients in the DHYZ group and 29 patients in the placebo group were analysed.
At week 12, nine of the 28 patients (32.1%) in the DHYZ group showed improved ASIA impairment grades (three from grade B to C, and six from grade C to D) and three of the 29 patients (10.3%) in the control group had improved ASIA grades (one from grade B to C, and two from grade C to D); the difference between the groups in the percentage of patients showing an improved ASIA grade was statistically significant (χ 2 = 4.07, P < 0.05).
Sensory scores at weeks 4, 8 and 12 were significantly higher than at week 0 in both groups (P < 0.05 for all; Table 3 ). There were no significant differences in sensory scores between the DHYZ and placebo groups at weeks 0, 4 and 8; however, the scores at week 12 were significantly higher (P < 0.05) in the DHYZ group than in the placebo group (Table 3) .
Motor scores at weeks 4, 8 and 12 were significantly higher than at week 0 in both groups (P < 0.05 for all; Table 4 ). There were no significant differences in motor scores between the DHYZ and placebo groups at weeks 0, 4 and 8; however, the scores at week 12 were significantly higher (P < 0.05) in the DHYZ group than in the placebo group (Table 4) .
Barthel index scores increased significantly from baseline values during the treatment period (P < 0.05 for all; Table 5 ). In addition, at weeks 8 and 12 the scores were significantly higher (P < 0.05 for both) in the DHYZ group than in the placebo group (Table 5 ).
Discussion
The therapeutic efficacy of Chinese herbs in SCI has not yet been confirmed in rigorous 
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clinical studies. The present placebocontrolled study is the first reported investigation of the efficacy of DHYZ in the treatment of SCI patients. Many studies have shown the importance of rehabilitation treatment after spinal injury, 24 -26 and the results of the present study suggest that DHYZ can enhance the effects of rehabilitation in SCI patients.
Secondary mechanisms of injury are crucial to the process of lesion expansion after SCI, and include vascular ischaemia 27, 28 and the formation of oxygen free radicals. 29 Apoptosis has also been shown to occur in SCI. 30, 31 Recent advances in understanding the pathophysiology of SCI have led to pharmacological strategies targeting the effects of secondary injury. 32 The combined effects of the constituents of DHYZ on secondary injury mechanisms may The precise mechanisms behind the ischaemia occurring in SCI are unclear, but vasospasm secondary to mechanical damage or vasoactive amines may be partially responsible. 28 Radix Aconiti Lateralis Preparata was reported to have positive inotropic, vasodilatory and diuretic effects in 35 patients with left ventricular failure. 33 The vasorelaxant effects of cinnamaldehyde, one of the major components in Cortex Cinnamomi, have been shown to include both endotheliumdependent and endothelium-independent effects. 34 Radix Rehmanniae Preparata has been reported to improve peripheral microcirculation in various chronic diseases through improvements in blood flow. 35 The neuroprotective effects of Radix Rehmanniae Preparata in cerebral ischaemia-induced neuronal and cognitive impairments have also been confirmed. 36 Radix Ginseng has been observed to suppress the formation of thrombin in blood coagulation and fibrinolysis. 37 Poria cocos has been shown to have a protective effect against brain ischaemia-reperfusion injury, 38 and ischaemia-induced neuronal and cognitive impairment. 36 Radix Angelica Sinensis significantly improved cognitive function in mice injured by repetitive cerebral ischaemia-reperfusion. 39 There is strong evidence for the early occurrence and pathophysiological importance of oxygen free radical formation and cell membrane lipid peroxidation in central nervous system injury, 29 and much work has been done examining the role of free radicals in SCI. 40 Several herbs in DHYZ have been reported to have inhibitory effects on the generation of oxygen free radicals, including Radix Ginseng, 41 Radix Aconiti Lateralis Preparata, 41 Cortex Cinnamomi, 42 -44 Radix Rehmanniae Preparata, 45 Fructus Corni, 46 Poria cocos, 47 Radix Angelica Sinensis 48 and Radix Glycyrrhizae. 48 Furthermore, Fructus Corni has also been found to protect vascular endothelial cells from oxidant injury 49 and Glycyrrhiza uralensis Fisch. has a promising role in the amelioration of ischaemia-reperfusion injury by acting as an antioxidant and oxygen radical scavenging agent. 50 These studies show that some of the ingredients of DHYZ may be useful for the treatment of disorders associated with oxidative damage.
It is thought that oligodendrocytes are the major type of cells that undergo apoptosis in compressive SCI, 51, 52 as demonstrated in the development of areas of Wallerian degeneration between 24 h and 3 weeks after injury. 30 Radix Ginseng may exert a protective effect against apoptosis in PC12 neuronal cells. 53 Poria cocos may protect nerve cells by suppressing the oxidative stress and apoptosis induced by amyloid β 1-42 . 54 Radix Angelica Sinensis had a pronounced protective effect against hydrogen peroxideinduced cytotoxicity by improving cellular antioxidant defence and inhibiting the mitochondrial apoptotic pathway. 55 Radix Glycyrrhizae has been shown to induce a 
cytoprotective effect against arsenite-induced cell death by inhibition of caspase-3. 56 Some of the other ingredients of DHYZ may also be beneficial to patients with SCI. For example, Ramulus Loranthi has been shown to promote the activation of macrophages, suggesting that it may possess the potential to regulate immune responses, 57 and Cortex Eucommiae may increase central nervous system excitability in mice. 58 Thus, there are a number of potential effects of herbs that may account for the efficacy of DHYZ in SCI patients.
The decoction DHYZ is an extract of Chinese herbs characterized by ready availability, affordability and versatility in clinical use. None of the patients in the present study experienced serious adverse side-effects, which suggests that DHYZ is not deleterious to SCI patients. The significant functional improvement seen in the present study with DHYZ treatment compared with placebo is encouraging and raises the possibility that this traditional Chinese medicine may be effective in improving neurological function during the subacute stage of SCI.
Patients with ASIA grade A SCI were not recruited to the present study because the prognosis for neurological and functional recovery in such patients is known to be poor. 59 However, the therapeutic results obtained with DHYZ in the present study in ASIA grade B -D patients are encouraging and warrant further investigation of the therapeutic value of DHYZ in ASIA grade A patients.
In conclusion, DHYZ, a drug made from traditional Chinese herbs, significantly improved neurological function in SCI patients compared with placebo and may be an effective adjuvant therapy to enhance functional recovery.
